WCLC 2022 | The identification of actionable mutations in lung cancer via ctDNA

Wanda Cui, MBBS, BMedSci, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the identification of actionable mutations in lung cancer via circulating tumor DNA (ctDNA). With single gene assays, rarer mutations can be missed or not tested for at all and thus not treated. Tissue-based next-generation sequencing (NGS) and ctDNA have a high concordance, but in terms of time to treatment, liquid biopsies offer a much faster approach than tissue testing. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.